BiomX PHGE
NYSE PHGE
$1.65 +0.00 (+0.00%)
As of: Sep 10, 2026 · 9:37 AM EDT

BiomX (PHGE) Other Non-Current Liabilities (2018 - 2026)

BiomX's (PHGE) quarterly Other Non-Current Liabilities came in at $2.4 million in Q2 2026, down 44.9% year-over-year from $4.4 million in Q2 2025, and up 44.04% quarter-over-quarter from $1.7 million in Q1 2026.

Analysis

BiomX (PHGE) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends

BiomX has disclosed Other Non-Current Liabilities across 9 years of filings, most recently posting $2.4 million for Q2 2026.

  • In Q2 2026, Other Non-Current Liabilities fell 44.9% year-over-year to $2.4 million; the TTM figure through Jun 2026 stood at $2.4 million (down 44.9% YoY), while the FY2025 annual figure was $706000.0, down 69.13% from the prior year.
  • Other Non-Current Liabilities came in at $2.4 million for Q2 2026 at BiomX, up from $1.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $24.9 million in Q2 2024 to a low of $148000.0 in Q3 2023.
  • Average Other Non-Current Liabilities over 5 years is $3.1 million, with a median of $706000.0 recorded in 2025.
  • Year-over-year, Other Non-Current Liabilities surged 12998.42% in 2024 and tumbled 82.3% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $188000.0 in 2022, then slipped by 17.55% to $155000.0 in 2023, then soared by 1375.48% to $2.3 million in 2024, then slumped by 69.13% to $706000.0 in 2025, then soared by 243.77% to $2.4 million in 2026.
  • Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $2.4 million in Q2 2026, $1.7 million in Q1 2026, and $706000.0 in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.28 Bn 197.29 Bn 7.24 Bn
2 Gilead Sciences 180.97 Bn 177.80 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.56 Bn 124.70 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.34 Bn 74.34 Bn 3.93 Bn
5 Argenx Se 60.73 Bn 55.54 Bn 1.37 Bn
6 Moderna 52.08 Bn 46.95 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.90 Bn 30.59 Bn 992.69 Mn
8 Biogen 31.21 Bn 29.93 Bn 1.96 Bn
9 Roivant Sciences 29.68 Bn 29.68 Bn 1.16 Mn
10 BiomX 17.27 Mn 16.70 Mn 97,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.43 Mn
Mar 31, 2026 1.69 Mn
Dec 31, 2025 706,000.00
Sep 30, 2025 5.14 Mn
Jun 30, 2025 4.41 Mn
Mar 31, 2025 5.90 Mn
Dec 31, 2024 2.29 Mn
Sep 30, 2024 4.33 Mn
Jun 30, 2024 24.89 Mn
Dec 31, 2023 155,000.00
Sep 30, 2023 148,000.00
Jun 30, 2023 190,000.00
Mar 31, 2023 192,000.00
Dec 31, 2022 188,000.00
Sep 30, 2022 206,000.00
Jun 30, 2022 209,000.00
Mar 31, 2022 215,000.00
Dec 31, 2021 215,000.00
Sep 30, 2021 420,000.00
Jun 30, 2021 419,000.00